ClinicalTrials.gg
CompletedNCT03062644STARDOM2Updated Sep 20, 2018

Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2.

A Phase 3 interventional study of MR308 and MR308 in Acute Pain, sponsored by Mundipharma Research GmbH & Co KG. Completed at 8 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-20.

Sponsored by Mundipharma Research GmbH & Co KG (part of Mundipharma) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,138
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing tramadol in Acute Pain — none open to participants now, 1 under way, none of them phase 3. Tramadol · Acute Pain.

Enrollment
2nd of 10
1,138 · median 263
Started
2017
with 1 other
Phase 3
2 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
2 of 10
Mundipharma Research GmbH & Co KG

Among the 10 studies testing tramadol in Acute Pain, this one is the 2nd largest by enrollment, is one of 2 that started in 2017, is one of 2 in phase 3, and was the 4th registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

Browse Acute Pain studies →

Open to participants now

None of the 10 studies testing tramadol in Acute Pain is open now. The open studies under Acute Pain, anywhere →

About tramadol

Tramadol: first FDA approval 1995 (ULTRAM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing tramadol in Acute Pain as a file.
02

Study summary

The MR308-3502 study is a multicenter double-blind, randomised, placebo- and active comparator-controlled study in female subjects to evaluate the efficacy and safety of MR308 with acute pain after TAH or STAH (total or subtotal abdominal hysterectomy).

Read the detailed description

This is a multicenter double-blind, randomised, placebo- and active comparator-controlled study in female subjects to evaluate the efficacy and safety of MR308 with acute pain after total or subtotal abdominal hysterectomy (TAH or STAH).

The screening Visit (Visit 1) can take place up to 28 days before the planned TAH or STAH. The surgery will be performed at Visit 2. Visit 2 consists of three different sections, a part before the surgery, the surgery and post surgery. On the next Day (Visit 3) subjects will qualify for further participation by regular measurements of their pain. Subjects meeting all eligibility criteria, such as defined pain levels, will be randomised to one of six treatment groups and be given IMPs for 120h. Subjects who will not be randomised are screen failures and will be given standard care as per local practice.

Visits 4, 5, 6 ,7 and 8, one to five days after randomisation will be performed to record efficacy and safety parameters.

The last dose of IMP should be taken by the subject about 120h after the initial dose and before Visit 8 (Completion/Discontinuation Visit) is performed.

The Adverse Event (AE) Follow up Visit (Visit 9) is the last study visit and should not be done earlier than seven days after the subject's last dose of IMP. It can be performed by telephone.

03

Conditions studied

  • Acute Pain

Browse trials for

Keywords

  • Open Total or Subtotal Abdominal Hysterectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female subjects ≥ 18 years on the day of consent.
  2. Willing and able to provide written for this study.
  3. Subjects are scheduled to have a total or subtotal abdominal hysterectomy under general anasethesia via a Pfannenstiel incision.
  4. The elective procedure (total or subtotal hysterectomy with or without salpingo-oophorectomy) must be for benign conditions within 28 days of screening. Subjects with stage 0 carcinoma in situ of cervix, endometrial hyperplasia or clinically staged 1A or 1B endometrial cancer are allowed to participate.
  5. American Society Anaesthesiology physical status of I or II.
  6. If a female is of , she must be using highly effective methods of throughout the study, not breastfeeding, and have negative pregnancy tests prior to receiving IMP. A highly effective method of birth control is defined as one which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner).
  7. Good general health as judged by Investigators on the basis of medical history and physical examination.
  8. Willingness to comply with the study procedures and requirements.

Additional Inclusion Criteria after Surgery:

  1. Abdominal hysterectomy completed without any immediate complication.
  2. Tolerating oral fluids, no uncontrolled nausea/vomiting and ready to take oral analgesia.
  3. The subject is alert and calm, spontaneously pays attention to caregiver, e.g. RASS = 0 (Sessler et al., 2002 \& Ely et al., 2003).
  4. Subjects will be capable to sit up from supine, stand up from a sitting position and walk 10 meters without assistance in the morning of the day following surgery.
  5. Subjects with moderate or severe pain (qualifying PI-VAS score ≥ 45mm and \< 70mm or ≥ 70mm and ≤ 90mm) as a result of a surgical procedure (abdominal hysterectomy) under general anaesthesia. This must be measured within a maximum of 24 hours after leaving the recovery room and subjects can only be randomised on the day after surgery, after cessation of the post-operative analgesia.

Exclusion criteria

Exclusion Criteria:

  1. Any abnormal laboratory value that is in the opinion of Investigator that would compromise the safety of the subject in the study.
  2. Any recent history of frequent nausea or vomiting, dizziness within the last 3 months regardless of etiology.
  3. Subjects having any medical condition or treatment that is either a warning or as per the SmPC of tramadol (e.g. selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, MAO inhibitors (within 14 days before taking IMP), antipsychotics, anticonvulsant and other seizure threshold-lowering medicinal products), celecoxib (e.g. increased risk of post-operative bleeding, active peptic ulceration, GI bleeding or inflammatory bowel disease) or paracetamol.
  4. Known sensitivity and/or contraindication to tramadol, celecoxib, paracetamol, sulfonamides, opioids, NSAIDS, COX-2 inhibitors, or related compounds or formulation as well as severe reactions (e.g. anaphylactic shock, bronchospasm, angioedema) to any drugs.
  5. Subjects who are known to have had inadequate pain relief from paracetamol, tramadol or celecoxib.
  6. Subjects requiring any medication which is prohibited as per section prohibited medication.
  7. Subjects who are in the Investigator's opinion considered at increased risk of operative (those associated with the surgical procedure and general anaesthesia) and post-operative complications, e.g. excessive post-operative bleeding, infection.
  8. Any history of drug or alcohol abuse, misuse, physical or psychological dependence, mood changes, sleep disturbance and functional capacity which have an impact on pain perception.
  9. Significant neurological or psychiatric disorders including mental instability (unrelated to the pain) that could interfere with pain assessment; other pre-existing or new non-abdominal/pelvic pain that might impair the assessment of the nociceptive pain.
  10. Any medical history of significant and/or inadequately controlled cardiovascular (uncontrolled high blood pressure, high risk of cardiovascular events, severe heart failure), pulmonary, hematologic, (including coagulopathy/bleeding disorders), neurological (e.g. subjects with epilepsy or those susceptible to seizures), liver disease (e.g. severe hepatic impairment), kidney disease (e.g. serum creatinine level greater than 1.5 times the , impaired renal function in subjects taking diuretics, ACE-inhibitors, or angiotensin II antagonists), endocrine, immunologic, dermatologic painful conditions or any other conditions that may compromise the ability of the subject to participate in the study or might interfere with drug absorption, distribution, metabolism or excretion.
  11. Previous randomisation in this study.
  12. Subjects who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days of study entry (defined as the start of the Screening Period).
  13. Subjects who were treated regularly with opioid analgesic or NSAIDs within 30 days prior to screening or who have received a long-acting NSAID within three days prior to the start of the surgery.
  14. Subjects who are incapable of complying with the protocol.
  15. Epidural or spinal anaesthesia or infiltration of the wound with an infusion of a local anaesthetic agent is not allowed. A single perioperative dose is allowed.
  16. History or ongoing chronic pelvic inflammatory disease or painful endometriosis.
  17. History of advanced gynaecological cancers.

Additional Exclusion Criteria after Surgery:

  1. Serious complication during surgery and up to randomisation, including:

    • Post-operative primary and secondary bleed that cannot be controlled.
    • Subjects who have not had the abdominal hysterectomy surgery completed as planned.
  2. If in the Investigator's opinion, there are any factors that may affect compliance with the protocol.
  3. Subject clinical need for antiemetics (apart from standard perioperative practice as defined in the protocol) or any other medication which is prohibited as per section prohibited medication.
  4. Subjects who have received any analgesic medication other than perioperative analgesia as described in the protocol.
  5. Any concerns that renal function has deteriorated, e.g. a laboratory parameter, profound hypotension, poor urine output or excessive bleeding during surgery.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,138 participants (actual)

Study arms

  • Experimental
    MR308 100 mg bid

    Tramadol/Celecoxib)

    Drug: MR308

  • Experimental
    MR308 150 mg bid

    Tramadol/Celecoxib

    Drug: MR308

  • Experimental
    MR308 200 mg bid

    Tramadol/Celecoxib

    Drug: MR308

  • Active comparator
    Tramadol 100 mg qid

    Tramadol

    Drug: MR308

  • Active comparator
    Celecoxib 100 mg bid

    Celecoxib

    Drug: MR308

  • Placebo comparator
    Placebo

    Placebo

    Drug: MR308

Interventions

  • DrugMR308

    two times daily; Mode of Administration:oral

    Also known as: Tramadol/Celecoxib

  • DrugMR308

    four times daily; Mode of Administration:oral

    Also known as: Tramadol

  • DrugMR308

    two times daily; Mode of Administration:oral

    Also known as: Celecoxib

  • DrugMR308

    given four times daily to maintain the blind; Mode of Administration:oral

    Also known as: Placebos

06

What researchers measure

Primary outcomes

  1. Efficacy of MR308 doses in the treatment of moderate to severe acute pain, based on the Sum of Pain Intensity Differences (SPID) from 0-4 hours.

    The primary efficacy endpoint is the Sum of Pain Intensity Differences over 0-4 hours (SPID4). SPID4 is derived as the weighted Sum of Pain Intensity Differences (baseline pain - current pain), measured at different time points via the PI-VAS. Time between two consecutive measurements will be used for weighting. Larger values indicate larger pain relief.

    Time frame: 0-4 hours

07

Study locations

8 sites
  • Minsk City Gynecology Hospital Department of Gynecology
    Minsk, 220007, Belarus
  • "Multiprofile Hospital for Active Treatment - Doverie" AD, Sofia Department of Gynecology
    Sofia, 1632, Bulgaria
  • Victoria Hospital - London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • Bajcsy-Zsilinszky Korhaz Szuleszet-Nogyogyaszati Osztaly
    Budapest, 1106, Hungary
  • Vidzeme Hospital Department of Gynecology and Obstetrics
    Valmiera, 4201, Latvia
  • Wojewódzki Szpital im. Św. Ojca Pio w Przemyślu Oddział Ginekologii i Położnictwa
    Przemysl, 37-700, Poland
  • Federal State Budgetary Institution National Medical-Surgical Centre named after N.I. Pirogov of the Ministry of Health of the Russian Federation Anesthesiology
    Moscow, 105203, Russian Federation
  • Hospital Universitari Germans Trias i Pujol Anestesia y Reanimación
    Barcelona, 08916, Spain
08

References and documents

Publications

  • Langford R, Morte A, Sust M, Cebrecos J, Vaque A, Ortiz E, Fettiplace J, Adeyemi S, Raba G, But-Husaim L, Gascon N, Plata-Salaman C. Efficacy and safety of co-crystal of tramadol-celecoxib (CTC) in acute moderate-to-severe pain after abdominal hysterectomy: A randomized, double-blind, phase 3 trial (STARDOM2). Eur J Pain. 2022 Nov;26(10):2083-2096. doi: 10.1002/ejp.2021. Epub 2022 Sep 24. PubMed 35974668 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Jun 2018, 14 months.

Of 29 industry-sponsored phase 3 interventional studies under Acute Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 14 months is above that.

Counting every sponsor, half of 54 studies reached it within 14 months; a quarter within 7 and three quarters within 25.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2017
First posted
Feb 23, 2017
StartActual
Apr 5, 2017
Primary completionActual
Jun 29, 2018
CompletionActual
Jun 29, 2018
Last update
Sep 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03062644
Responsible party
Sponsor
First posted
Feb 23, 2017
Start date
Apr 5, 2017
Primary completion
Jun 29, 2018
Completion
Jun 29, 2018
Last update
Sep 20, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tramadol · Celecoxib

Start the discussion